Range Financial Group LLC Has $2.91 Million Stock Position in Cencora, Inc. (NYSE:COR)

Range Financial Group LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 14.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,447 shares of the company's stock after buying an additional 1,333 shares during the period. Cencora comprises 1.3% of Range Financial Group LLC's investment portfolio, making the stock its 17th largest holding. Range Financial Group LLC's holdings in Cencora were worth $2,905,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JFS Wealth Advisors LLC raised its holdings in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares during the period. Banque Transatlantique SA acquired a new position in shares of Cencora in the 4th quarter valued at about $29,000. SBI Securities Co. Ltd. acquired a new position in shares of Cencora in the 4th quarter valued at about $30,000. Kentucky Trust Co acquired a new position in shares of Cencora in the 4th quarter valued at about $33,000. Finally, WASHINGTON TRUST Co increased its holdings in shares of Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on COR. Citigroup upped their target price on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Morgan Stanley set a $288.00 target price on Cencora in a report on Tuesday, April 15th. Robert W. Baird upped their target price on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Finally, Bank of America upped their target price on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $306.91.

Cencora Price Performance

Cencora stock traded up $8.32 during mid-day trading on Thursday, hitting $294.96. 1,418,060 shares of the company were exchanged, compared to its average volume of 1,525,273. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The business has a fifty day moving average of $286.42 and a 200 day moving average of $260.98. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The company has a market capitalization of $57.17 billion, a PE ratio of 41.96, a price-to-earnings-growth ratio of 1.31 and a beta of 0.58.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm had revenue of $75.50 billion for the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter last year, the business earned $3.80 earnings per share. The company's revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Insider Activity

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of Cencora stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the transaction, the executive vice president now owns 14,665 shares in the company, valued at $3,934,326.20. The trade was a 21.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the transaction, the chief executive officer now owns 47,582 shares in the company, valued at $13,766,900.06. This trade represents a 9.46% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,253 shares of company stock worth $10,582,297 in the last 90 days. Corporate insiders own 10.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.